Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTRB NASDAQ:NXGL NASDAQ:TELA NASDAQ:VANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTRBNutriband$6.47-0.9%$7.57$3.72▼$11.78$72.84M1.13189,340 shs7,398 shsNXGLNexGel$2.45$2.47$2.10▼$5.10$19.77M0.5753,463 shs28,676 shsTELATELA Bio$1.78-1.1%$1.86$0.86▼$3.26$71.31M0.9399,139 shs54,737 shsVANIVivani Medical$1.15-2.5%$1.35$0.91▼$1.80$69.91M2.99135,682 shs63,094 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTRBNutriband-0.92%+0.62%-9.13%+4.02%+44.42%NXGLNexGel0.00%+5.60%+8.41%+11.87%-13.27%TELATELA Bio-1.11%+0.56%-8.25%+27.14%-39.25%VANIVivani Medical-2.54%-7.26%-19.58%-7.28%-12.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNTRBNutriband3.2514 of 5 stars3.55.00.00.02.71.70.6NXGLNexGel1.3588 of 5 stars0.05.00.00.02.52.50.0TELATELA Bio2.9228 of 5 stars3.34.00.00.03.11.70.6VANIVivani Medical2.3523 of 5 stars3.53.00.00.02.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTRBNutriband 3.00Buy$13.00100.93% UpsideNXGLNexGel 0.00N/AN/AN/ATELATELA Bio 2.50Moderate Buy$4.50152.81% UpsideVANIVivani Medical 3.00Buy$4.00247.83% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTRBNutriband$2.14M33.71N/AN/A$0.58 per share11.16NXGLNexGel$11.67M1.69N/AN/A$0.63 per share3.89TELATELA Bio$69.30M1.02N/AN/A$0.23 per share7.74VANIVivani MedicalN/AN/AN/AN/A$0.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTRBNutriband-$10.48M-$0.90N/AN/AN/A-415.93%-68.25%-60.40%9/2/2025 (Estimated)NXGLNexGel-$3.28M-$0.40N/A∞N/A-25.02%-49.37%-25.68%11/12/2025 (Estimated)TELATELA Bio-$37.84M-$1.12N/AN/AN/A-54.12%-329.48%-57.34%11/6/2025 (Estimated)VANIVivani Medical-$23.49M-$0.45N/AN/AN/AN/A-194.66%-68.64%11/12/2025 (Estimated)Latest NXGL, TELA, NTRB, and VANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/2/2025N/ANTRBNutriband-$0.17N/AN/AN/A$0.71 millionN/A8/13/2025Q2 2025VANIVivani Medical-$0.10-$0.12-$0.02-$0.12N/AN/A8/12/2025Q2 2025NXGLNexGel-$0.07-$0.09-$0.02-$0.09$3.08 million$2.88 million8/11/2025Q2 2025TELATELA Bio-$0.18-$0.22-$0.04-$0.22$20.67 million$20.20 million5/30/2025Q1 2026NTRBNutriband-$0.13-$0.12+$0.01-$0.12$0.71 million$0.67 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNTRBNutribandN/AN/AN/AN/AN/ANXGLNexGelN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTRBNutriband0.013.713.48NXGLNexGel0.161.740.98TELATELA Bio4.143.192.59VANIVivani MedicalN/A1.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTRBNutriband19.70%NXGLNexGel2.21%TELATELA Bio94.35%VANIVivani Medical6.78%Insider OwnershipCompanyInsider OwnershipNTRBNutriband54.09%NXGLNexGel20.55%TELATELA Bio4.70%VANIVivani Medical46.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTRBNutriband1011.15 million5.12 millionNot OptionableNXGLNexGel108.07 million6.41 millionNot OptionableTELATELA Bio12039.62 million37.75 millionOptionableVANIVivani Medical2059.24 million31.76 millionOptionableNXGL, TELA, NTRB, and VANI HeadlinesRecent News About These CompaniesA brewing GLP-1 showdown, from Big Pharma pills to a biotech implantAugust 27 at 10:19 AM | finance.yahoo.comOzempic for dogs? I’d happily put my food-obsessed golden retriever on ‘Wagovy’August 24, 2025 | aol.comAAre weight-loss jabs for dogs the next big thing? Scientists exploring new solutions for pet obesityAugust 22, 2025 | msn.comOzempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We KnowAugust 22, 2025 | msn.comCould Dogs Get Their Version Of Ozempic? Scientists Test "Ozempup" For Pet ObesityAugust 21, 2025 | ndtv.comNAfter Ozempic, is “Ozempup” on the way? Scientists explore weight-loss jabs for obese pet dogs-- All details hereAugust 21, 2025 | msn.comVivani Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference on Innovative Drug Implant TechnologyAugust 20, 2025 | quiverquant.comQVivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025August 20, 2025 | globenewswire.comFido get fat? Ozempic for dogs could hit the market in three yearsAugust 19, 2025 | msn.comVivani Medical (NASDAQ:VANI) Stock Price Down 0.8% After Earnings MissAugust 15, 2025 | marketbeat.comVivani Medical (NASDAQ:VANI) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comVivani closes $10M financing, advances GLP-1 implantAugust 14, 2025 | drugdeliverybusiness.comDVivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deVivani Medical Reports Q2 2025 Results and $10M FinancingAugust 13, 2025 | tipranks.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second ...August 13, 2025 | bakersfield.comBVivani Medical Secures $10M Through Share Purchase AgreementAugust 13, 2025 | msn.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comVivani Medical (VANI) to Release Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comVivani Medical, Inc. (NASDAQ:VANI) Sees Large Growth in Short InterestAugust 2, 2025 | marketbeat.com3 Penny Stocks With Market Caps Over $30M To ConsiderJuly 16, 2025 | finance.yahoo.comVivani Medical Insiders Added US$5.29m Of Stock To Their HoldingsJune 30, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNXGL, TELA, NTRB, and VANI Company DescriptionsNutriband NASDAQ:NTRB$6.47 -0.06 (-0.92%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.47 0.00 (0.00%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.NexGel NASDAQ:NXGL$2.45 0.00 (0.00%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$2.46 +0.00 (+0.20%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.TELA Bio NASDAQ:TELA$1.78 -0.02 (-1.11%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 08/29/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Vivani Medical NASDAQ:VANI$1.15 -0.03 (-2.54%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.20 +0.05 (+4.35%) As of 08/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
